ThermoGenesis Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US88362L2097
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

644

Shareholding (Mar 2024)

FII

0.00%

Held by 3 FIIs

DII

99.56%

Held by 0 DIIs

Promoter

0.00%

How big is ThermoGenesis Holdings, Inc.?

22-Jun-2025

As of December 2023, ThermoGenesis Holdings, Inc. has an unavailable market capitalization, reported net sales of $9.61 million, a net loss of $15.74 million, negative shareholder funds of $1.67 million, and total assets of $11.23 million.

As of December 2023, ThermoGenesis Holdings, Inc. has a market capitalization value that is not available, which indicates that it may fall into a category that is not classified as Large Cap, Mid Cap, or Small Cap.<BR><BR>As of December 2023, the company reported net sales of 9.61 million for the latest four quarters, while the net profit for the same period was a loss of 15.74 million.<BR><BR>As of December 2023, the shareholder's funds were reported at -1.67 million, and the total assets amounted to 11.23 million.

Read More

Should I buy, sell or hold ThermoGenesis Holdings, Inc.?

22-Jun-2025

Who are in the management team of ThermoGenesis Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of ThermoGenesis Holdings, Inc. includes Dr. Xiaochun Xu as Chairman, President, and CEO, along with independent directors Ms. Debra Donaghy, Dr. Russell Medford, Dr. Joseph Thomis, and Mr. Mark Westgate.

As of March 2022, the management team of ThermoGenesis Holdings, Inc. includes Dr. Xiaochun Xu, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features several independent directors: Ms. Debra Donaghy, Dr. Russell Medford, Dr. Joseph Thomis, and Mr. Mark Westgate.

Read More

Is ThermoGenesis Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, ThermoGenesis Holdings, Inc. has shifted from a mildly bearish to a sideways trend, with a year-to-date return of -100.0%, indicating a neutral stance due to a lack of upward momentum.

As of 2 September 2025, the technical trend for ThermoGenesis Holdings, Inc. has changed from mildly bearish to sideways. The stock has experienced a significant decline, with a year-to-date return of -100.0% compared to the S&P 500's positive return of 12.22%. Overall, the current stance is neutral, reflecting a lack of upward momentum despite the change in trend.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

3.67

stock-summary
Return on Equity

-1,361.50%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Mar 2024)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
-85.71%
0%
-85.71%
2 Years
-99.99%
0%
-99.99%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

ThermoGenesis Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.25%
EBIT Growth (5y)
4.13%
EBIT to Interest (avg)
-0.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.67
Sales to Capital Employed (avg)
0.98
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.79%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
-0.60
EV to EBITDA
-0.75
EV to Capital Employed
0.79
EV to Sales
0.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-130.99%
ROE (Latest)
-1361.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.44%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 12.50% vs 9.09% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2024 is 73.68% vs -105.41% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.70",
          "val2": "2.40",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.20",
          "val2": "-1.90",
          "chgp": "89.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "3.30",
          "chgp": "-54.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-7.60",
          "chgp": "73.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-203.50%",
          "val2": "-931.80%",
          "chgp": "72.83%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -10.48% vs 12.90% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -60.17% vs 0.84% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.40",
          "val2": "10.50",
          "chgp": "-10.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.40",
          "val2": "-5.30",
          "chgp": "-1.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.00",
          "val2": "5.60",
          "chgp": "78.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.90",
          "val2": "-11.80",
          "chgp": "-60.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-696.00%",
          "val2": "-590.80%",
          "chgp": "-10.52%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQstock-summary
Mar'24
Dec'23
Change(%)
Net Sales
2.70
2.40
12.50%
Operating Profit (PBDIT) excl Other Income
-0.20
-1.90
89.47%
Interest
1.50
3.30
-54.55%
Exceptional Items
0.00
-2.00
100.00%
Consolidate Net Profit
-2.00
-7.60
73.68%
Operating Profit Margin (Excl OI)
-203.50%
-931.80%
72.83%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2024 is 12.50% vs 9.09% in Dec 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2024 is 73.68% vs -105.41% in Dec 2023

Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
9.40
10.50
-10.48%
Operating Profit (PBDIT) excl Other Income
-5.40
-5.30
-1.89%
Interest
10.00
5.60
78.57%
Exceptional Items
-2.40
-0.00
Consolidate Net Profit
-18.90
-11.80
-60.17%
Operating Profit Margin (Excl OI)
-696.00%
-590.80%
-10.52%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -10.48% vs 12.90% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -60.17% vs 0.84% in Dec 2022

stock-summaryCompany CV
About ThermoGenesis Holdings, Inc. stock-summary
stock-summary
ThermoGenesis Holdings, Inc.
Pharmaceuticals & Biotechnology
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.
Company Coordinates stock-summary
Company Details
2711 Citrus Rd , RANCHO CORDOVA CA : 95742-6228
stock-summary
Tel: 1 916 8585100
stock-summary
Registrar Details